MTVA news

MetaVia announced Phase 1 data showing a 68% placebo-adjusted reduction in liver fat and 13.5% weight loss, indicating strong clinical progress toward treating liver-related cardiometabolic diseases.

MetaVia announced acceptance for an oral presentation of Phase 1 data for dual receptor agonist DA-1726, showing potential for weight loss and liver benefits.

MetaVia announces Dr. Sarah Browne as Chief Medical Officer to advance its portfolio of cardiometabolic drugs, including Phase 3 candidate DA-1726, stimulating investor interest in the company's pipeline potential.

All active patients in MetaVia's Phase 1 Part 3 obesity study reached target doses, indicating favorable tolerability for DA-1726. The company projects no delays to its Q4 2026 top-line data timeline.

MetaVia announced Phase 1 results for DA-1726 showing up to 9.1% mean body weight reduction and preclinical data supporting combination therapies for metabolic diseases. The data demonstrates potential differentiation of the company's cardiometabolic pipeline and supports advancement toward higher-d…

MetaVia presented Phase 1 results for DA-1726 showing up to 9.1% mean body weight reduction at 48 mg dose with favorable safety and early liver improvements at EASL 2026. The dual GLP-1/glucagon receptor agonist demonstrates potential for obesity and MASH treatment with ongoing Phase 1 titration stu…